Stockreport

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes [TheStreet.com]

Lixte Biotechnology Holdings, Inc.  (LIXT) 
NASDAQ:AMEX Investor Relations: lixte.com/investor_information_02.php
PDF LB-100 helps in the fight against cancer in a few ways, as it makes cancer cells more sensitive to immunotherapy and chemotherapy, while also disrupting cancer's intern [Read more]